Skip to main content

Table 1 Annual mean (95 % CI) number of SHEs in patients with T1 and T2 DM

From: Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis

Therapy Average number of SHEs per patient per year Probability of ≥1 SHE for a patient annually
T1
Insulin pump 0.168 (0.123–0.237) 11.38 % (8.09 %–16.03 %)
Basal-bolus (basal insulin analogue) 0.472 (0.252–1.055) 21.37 % (11.30 %–42.97 %)
Basal-bolus (basal human insulin) 1.084 (0.530–2.900) 33.77 % (17.93 %–67.53 %)
T2
BOT analogue 0.113 (0.050–0.324) 5.55 % (2.32 %–15.62 %)
BOT human 0.173 (0.072–0.600) 7.95 % (3.18 %–26.35 %)
Basal-bolus (basal insulin analogue) 0.080 (0.027–0.456) 4.78 % (1.21 %–27.04 %)
Basal-bolus (basal human insulin) 0.554 (0.157–7.534) 31.40 % (7.44 %–99.64 %)
Pre-mix insulin analogue 0.092 (0.052–0.186) 6.23 % (3.41 %–12.49 %)
Pre-mix human insulin 0.299 (0.137–0.868) 12.43 % (5.87 %–31.85 %)
Sulfonylureas 0.045 (0.023–0.115) 3.57 % (1.91 %–7.56 %)
  1. BOT Basal therapy combined with oral antidiabetic medication, SHE Severe hypoglycaemia event, T1, T2 DM Type 1, Type 2 diabetes mellitus